Short interest for Astria Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Astria Therapeutics's stock. Short interest data is updated every two weeks.

Astria Therapeutics Stock (NASDAQ:ATXS), Short Interest Report

Astria Therapeutics

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADVM

AISP

ANGH

ANVS

AQST

ATER

ATXS

BCAN

BLDE

BNRG

BNTX

CETX

CMAX

DWAC

EGIO

ETAO

HROW

IREN

LFCR

MARA

MNTS

OBLG

OTRK

SEEL

SKIN

SRAD

SWVL

TRUG

TSHA

WORX

WULF

XTLB

Shares of  Lifecore Biomedical, Inc.  (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes.

Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday.

Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Long Ideas

Insider Trades

Pre-Market Outlook

STCN

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.

$5.6M Bet On This Real Estate Stock? Check Out These 3 Stocks Insiders Are Buying

Price Target

Analyst Ratings

ETWO

FSLR

HYLN

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Exxon Mobil To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Thursday

Astria Therapeutics Inc

BZFD

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BZFDW

&nbsp;Vizsla Silver Corp. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/VZLA#TSXV">VZLA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZLA#NYSE">VZLA</a>) (Frankfurt: 0G3) ("Vizsla Silver" or the "Company") is pleased to announce that it has now issued 448,137 common shares (the "Consideration Shares") for the previously announced asset purchase agreement (the "Acquisition Agreement") dated March 5, 2024, entered into with Inca Azteca Gold S.A.P.I. de C.V. (the "Seller") and the Company's wholly owned subsidiary, Minera Canam, S.A. de C.V. ("Minera Canam") pursuant to which the Company agreed to acquire, through Minera Canam, all of the Seller's right, title and interest in and to the mineral concessions (the "Acquisition").&nbsp;
The Company will acquire two large claims comprising 10,667.0 Ha (the "El Richard – San Enrique claims" or "San Enrique prospect") located south and partially adjacent to the Company's Panuco project (the "Panuco Project" or "Panuco").&nbsp; The San Enrique prospect is situated along the highly prospective Panuco – San Dimas corridor and is covered 100% with LiDAR and partially covered with high-resolution aero-magnetic and radiometric surveys.

TSXV:VZLA

VZLA

Vizsla Silver Provides Further Update On Acquisition Of Large Claim Package Along Highly Prospective Structural Trend, South Of Panuco

<a href="https://www.nytimes.com/2024/05/03/business/media/paramount-skydance-exclusive-talks-lapse.html#:~:text=Paramount's%20special%20committee%20is%20set,broadcast%20networks%2C%20like%20Paramount's%20CBS.">https://www.nytimes.com/2024/05/03/business/media/paramount-skydance-exclusive-talks-lapse.html#:~:text=Paramount's%20special%20committee%20is%20set,broadcast%20networks%2C%20like%20Paramount's%20CBS.</a>
&nbsp;
Paramount told Skydance that it would not extend the Hollywood studio's exclusive window to negotiate a merger, two people with knowledge of the decisions said Friday, imperiling the deal but opening the door to other suitors for the owner of MTV and Nickelodeon.
The development throws up a major roadblock for Skydance, a movie studio that has been negotiating a complicated deal to merge with Paramount for months. Many Paramount investors have come out against that deal, saying it would <a href="https://www.nytimes.com/2024/04/04/business/media/paramount-board-shari-redstone.html">enrich Shari Redstone</a>, the company's board chair, at the expense of other shareholders.
The 30-day period for exclusive talks with a special committee of Paramount's board expires at the end of Friday. It is unclear what Skydance, which was founded by the tech scion and producer David Ellison, and its backer, RedBird Capital Partners, will do next. The company could wait for Paramount to re-engage in negotiations, could make a higher bid or could walk away. The company is wary of being used by Paramount to drive up the price for another bidder.
Paramount's special committee will now probably focus on negotiating with another suitor, Sony Pictures Entertainment, which has teamed up with the private equity giant Apollo Global Management to make <a href="https://www.nytimes.com/2024/05/02/business/media/sony-apollo-paramount-deal.html">a $26 billion bid</a> for the company. Paramount's shareholders prefer the all-cash offer — which would include the assumption of Paramount's debt — because it would give them a substantial premium on the company's current stock price.
&nbsp;
Paramount's special committee is set to meet on Saturday to discuss the deal, the two people with knowledge of the company's plans said.
The deal with Sony and Apollo is not without its own risk. Government regulations restrict foreign ownership of broadcast networks, like Paramount's CBS. Sony Pictures Entertainment is a division of the Tokyo-based Sony Group, and it's unlikely that it could obtain a license to own CBS. But there are potential remedies to that problem: Apollo could apply to hold the license to CBS, or the group could decide to sell the network.
Paramount's fate ultimately lies in Ms. Redstone's hands. Her control of National Amusements, Paramount's parent company, gives her the power to block any deal. Ms. Redstone has already signed off on a potential deal between Skydance and National Amusements that would allow her to sell her stake for around $2 billion, but that deal hinges on approval of a merger of Paramount and Skydance.
CNBC earlier <a href="https://www.cnbc.com/2024/05/03/paramount-news-skydance-could-drop-bid-after-sony-apollo-offer.html">reported</a> that Paramount was planning to end exclusive negotiations with Skydance.

PARA

PARAA

"Paramount Will Let Exclusive Talks With Skydance Lapse, Imperiling Deal; Negotiations Are Now Likely To Focus On Another Suitor, Sony, Which Has Teamed Up With The Private Equity Giant Apollo On A $26B Bid" - NY Times

Earnings

HCWB

HCW Biologics Says Due To Default Issue, Concluded Financial Statements As Of & For Year Ended Dec 31, 2023 Should Be Restated & No Longer Be Relied Upon

Contracts

On May 1, Eagle Materials Inc TLCC Partners, HM, HMSC Entered Into A Put Option Agreement; Under Agreement, TLCC Partners Granted Put Option To HMSC; Put Option Entitles HMSC To Require TLCC Partners To Purchase All Partnership Interests Held By HMSC In JV; Under Put Option, TLCC Partners To Buy All Partnership Interests Of HMSC In JV For Payment Of Amount Equal To 50% Of $1.1B

Growing wealth is not as difficult as it seems, according to a self-made millionaire Ramit Sethi. It's easy enough that Sethi thinks it takes only three "deceptively" simple steps to accumulate wealth and gain financial independence.
Sethi is the author of the book "I Will Teach You To Be Rich" which outlines a six-week process to help readers choose the right investments to make sure their money grows.
Whether you're worried about your home loans, student loans, or any other debt, or if it's about asking for that big raise you've been eyeing, Sethi has a strategy for you.
Sethi revealed three "boring" and "deceptively" simple steps to grow wealth, in an earlier interview <a href="https://www.cnbc.com/2023/07/07/self-made-millionaire-ramit-sethi-no-1-way-to-grow-your-wealth.html">with</a> CNBC.
<h2 class="wp-block-heading">Three Steps To Grow Your Wealth</h2>
<h3 class="wp-block-heading">1. Start Investing And Increase It Steadily</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03083837/Wealth-1-1024x576.jpg" alt="" class="wp-image-321378" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03083837/Wealth-1-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03083837/Wealth-1-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03083837/Wealth-1-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03083837/Wealth-1-1536x864.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03083837/Wealth-1.jpg 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Representational image of a person investing &#x7C; Photo courtesy: Dall-E</figcaption></figure>
The first step to becoming wealthy is to start investing. It's a habit and once formed, you can set it on autopilot and let the money grow itself.
"Invest a percentage of your income every year automatically and increase that percentage 1%."
Suppose you're wondering whether your investments can perform as well as those of rich people who have access to options that regular people don't. In that case, Sethi says they "typically do not perform better than a simple S&amp;P index fund."
Identify a simple low-cost index fund and get going.
<h3 class="wp-block-heading">2. Ask For The Salary You Want And Deserve</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084055/Wealth-2-1-1024x576.jpg" alt="" class="wp-image-321383" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084055/Wealth-2-1-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084055/Wealth-2-1-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084055/Wealth-2-1-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084055/Wealth-2-1-1536x864.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084055/Wealth-2-1.jpg 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Representational image of two people in an office &#x7C; Photo courtesy: Shutterstock</figcaption></figure>
Investing is one side of the wealth journey. Making sure you're able to invest consistently is the other aspect. For most people, the source is salary, and making sure you're getting the right salary is important.
"Learn the skills of negotiating your salary and getting paid what you're worth," says Sethi.
One good way to make sure you're getting paid right is by checking what others in the same position as you are being paid.
<h3 class="wp-block-heading">3. Develop A Side Hustle</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084119/Wealth-3-1024x576.jpg" alt="" class="wp-image-321384" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084119/Wealth-3-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084119/Wealth-3-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084119/Wealth-3-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084119/Wealth-3-1536x864.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/03084119/Wealth-3.jpg 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Representational image of a person working &#x7C; Photo courtesy: Dall-E</figcaption></figure>
While not everyone is a fan of hustling, the journey to making wealth requires you to put in that extra effort.
"If you really want to increase your earnings, consider starting a business on the side," suggests Sethi.
This hustle could be anything you like – the only idea is that you get more money out of it than you put in. It can even be a hobby, provided it can be made profitable.
Image from Shutterstock

Personal Finance

'I Will Teach You To Be Rich' Author, Ramit Sethi, Became A Self-Made Millionaire — He Now Shares His Simple Formula To Grow Your Wealth

In Q1, Citigroup Got Notification From FDIC That FDIC Special Assessment Estimate To Increase To $20.4B; In Q1, Increased Its Total Accrued Estimated Liability To $2B For The FDIC Special Assessment

CLIR

On May 2, Clearsign Technologies Received Letter From Nasdaq That Company No Longer Meets The Minimum Bid Price Requirement

ADTN

Adtran Impairment Assessment Was Triggered As A Result Of Factors Such As A Decrease In Co's Market Capitalization; Impairment Assessment Was Triggered As A Result Of Factors Such As Cautious Service Provider Spending Due To Economic Uncertainty

Adtran Determined That A Material Charge For Impairment To Goodwill Will Be Required For Q1 Of 2024; Impairment Leads To An Increased GAAP Operating Loss For Q1 2024 By Same Amount; Charge Has No Impact On Co's Compliance With Covenants Under Its Credit Agreement; Non-Cash Goodwill Impairment On Carrying Amount Of Goodwill Solely Allocated To Network Solutions Segment Estimated Around $293M

AAON

S&P Dow Jones Indices Says Marathon Digital Holdings Inc. Will Replace AAON In The S&P Smallcap 600 Effective Prior To The Market Open On May 8

S&P Dow Jones Indices Says AAON Inc. Will Replace Vistra In The S&P Midcap 400 Effective Prior To The Market Open On May 8

S&P Dow Jones Indices Says Vistra Corp. Will Replace Pioneer Natural Resources Co. In The S&P 500 Effective Prior To The Market Open On May 8

QDRO

Quadro Acquisition One Provided Notice To NHC Holdings II That It Has Terminated Business Combination Agreement

IPOs

Zeekr Intelligent Technology Holding Ltd Sees IPO Price In Range Of $18-$21/ADS; Existing Shareholders, Third-Party Investors Indicated To Subscribe Up To $349.1M Of ADSs Being Offered In IPO; Sees U.S. Ipo Of 17.5M ADSs; Plans To Use About $138.9MOf IPO Proceeds, To Develop More Advanced Bev Technologies, Expansion Of Product Portfolio; Plans To Use About $138.9M, For Selling, Marketing, Expansion Of Service And Charging Network

Offerings

LAZR

Luminar Files For Mixed Shelf; Size Not Disclosed

Management

On April 30, Seelos Therapeutics Inc  Announced A Reduction In Its Workforce That Affected ~33% Of Its Current Employees; Company Received Bid Notice From Nasdaq Stock Market

Velocity Financial Entered Into Separate Equity Distribution Agreements With Each Of BTIG, LLC And Virtu Americas LLC; Under Agreements, Co May Sell, From Time To Time, Shares Of Co's Common Stock With Offering Price Of Up To $50M

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Astria Therapeutics (ATXS – Research Report), with a price target of $18.00. Sam ...

Buy Rating on Astria Therapeutics: Anticipating Market Growth with STAR-0215's Advancements in HAE Treatment

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on ATXS stock, giving a Buy rating on March 11. Joseph Pantginis has g...

Astria Therapeutics: A Strong Buy on Promising ALPHA-STAR Trial and Potential Market Edge with STAR-0215

The 80 rating InvestorsObserver gives to Astria Therapeutics Inc (ATXS)  stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 95 percent of stocks in the Biotechnology industry, ATXSâ€&#x2122;s 80 overall rating means the stock scores better than 80 percent of all stocks. ATXS has an Overall

Where Does Astria Therapeutics Inc (ATXS) Stock Fall in the Biotechnology Field After It Has Risen 5.92% This Week?

The 61 rating InvestorsObserver gives to Astria Therapeutics Inc (ATXS)  stock puts it near the top of the Healthcare sector.In addition to scoring higher than 88 percent of stocks in the Healthcare sector, ATXS's 61 overall rating means the stock scores better than 61 of all stocks. ATXS has an Overall Score of 61. Find o

Should You Add Astria Therapeutics Inc (ATXS) Stock to Your Portfolio Monday?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Harmony Biosciences Holdings (HRMY – Research Report) and Astria ...

Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Astria Therapeutics (ATXS)

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Astria Therapeutics (ATXS – Research Report). The associated price targe...

Buy Rating Affirmed for Astria Therapeutics on Promising STAR-0215 Data and Market Potential

Analyst Michael Higgins of Ladenburg Thalmann & Co. maintained a Buy rating on Astria Therapeutics (ATXS – Research Report), with a price target of...

Buy Recommendation for Astria Therapeutics Backed by Promising ALPHA-STAR Trial Results

Wedbush analyst Laura Chico maintained a Buy rating on Astria Therapeutics (ATXS – Research Report) today and set a price target of $22.00. The com...

Wedbush Remains a Buy on Astria Therapeutics (ATXS)

The latest update is out from Astria Therapeutics (ATXS). Astria Therapeutics, Inc. expanded its Board of Directors from eight to nine members and ...

Astria Therapeutics Expands Board, Appoints New Director

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Legend Biotech (LEGN – Research Report), Astria Ther...

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)

ASLN

HRMY

LEGN

Press Releases

Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting

Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Astria Therapeutics Stock (NASDAQ:ATXS), Short Interest Report

People Also Watch